Preferred Label : PD-L1 Inhibitor BPI-371153;
NCIt definition : An orally bioavailable, small molecule inhibitor of the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon oral administration,
PD-L1 inhibitor BPI-371153 specifically targets and binds to PD-L1 expressed on tumor
cells, thereby preventing the binding to and subsequent activation of its receptor,
programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell
inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances
the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing
tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed
in some cancer types and plays a significant role in immune evasion by tumor cells.;
Molecule name : BPI 371153; BPI-371153;
NCI Metathesaurus CUI : CL1792168;
Origin ID : C187338;
UMLS CUI : C5706406;
Semantic type(s)
- concept_is_in_subset
- has_target
